Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 36,678

Document Document Title
WO/2024/032529A1
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...  
WO/2024/032409A1
The present application relates to the use of a piperazine compound in combination with radiotherapy for the treatment of a tumor.  
WO/2024/035627A1
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.  
WO/2024/032689A1
The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer thereof, a stereoisomer thereof, a solvate thereof, or a polymorph thereof, and use thereof. The present disclosure further relates to a pharmac...  
WO/2024/033293A1
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).  
WO/2024/032569A1
The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a...  
WO/2024/032561A1
Described herein are inhibitors of cyclin-dependent kinase (CDK) 12 and/or CDK13 (and pharmaceutical compositions comprising the inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...  
WO/2024/032776A1
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2024/032782A1
Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...  
WO/2024/033667A1
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...  
WO/2024/029489A1
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...  
WO/2024/027762A1
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and a use thereof. The present invention provides the fused ring compound represented by formula (I), a stereoisomer thereof, or a pharmaceut...  
WO/2024/030968A1
The present disclosure relates to protein degradation-inducing compounds for protooncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorder...  
WO/2024/031089A1
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.  
WO/2024/027795A1
An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...  
WO/2024/027703A1
Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...  
WO/2024/027694A1
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...  
WO/2024/026536A1
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...  
WO/2024/028727A1
The present invention discloses a novel type of highly potent ENPP-1 inhibitors for the treatment of various diseases particularly, cancer. These inventive inhibitors are small molecules. One of the novel structural features is incorpora...  
WO/2024/028795A1
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...  
WO/2024/030908A1
The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI an...  
WO/2024/028519A1
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...  
WO/2024/027565A1
The present invention relates to a crystal form of a compound of formula (I), i.e. (2-((5-chloro-2-((2-methoxy-4-(9-methyl-3,9-diaza-spiro[5.5] undecane-3-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimet hylphosphine oxide. The present ...  
WO/2024/028169A1
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...  
WO/2024/028744A1
The present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA). The invention also describes the preparation of su...  
WO/2024/027800A1
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...  
WO/2024/027116A1
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...  
WO/2024/026688A1
The present invention relates to an orange-red thermally activated delayed fluorescent material and a preparation method therefor. The material name is 4,4',4''-(dibenzo[f,h]pyrido[2,3-b]quinoxaline-3,6,11-triyl) tri(N,N-diphenylaniline)...  
WO/2024/028316A1
The present invention relates to 1H-pyrrolo[3,2-b]pyridine derivatives of formula (I) as irreversible inhibitors of mutant EGFR for the treatment of cancer. An exemplary compound is e.g. N-[2-({4-[3-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyri...  
WO/2024/026540A1
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention r...  
WO/2024/028245A1
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransfera...  
WO/2024/026058A1
The present invention provides crystalline forms of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2 H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4( 1H,3H)-dione ("Compound I"). Also provided are related pharmace...  
WO/2024/022434A1
The present application relates to a substituted pyridocycloheptane derivative, a preparation method therefor, and use of a pharmaceutical composition comprising the derivative or a deuterated derivative in medicine. In particular, the p...  
WO/2024/026500A2
PDE11A4 inhibitors, and methods of using the same, are provided for treating or preventing diseases or disorder associated with cognitive decline.  
WO/2024/026290A1
The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...  
WO/2024/026338A1
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.  
WO/2024/026359A1
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...  
WO/2024/022266A1
The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...  
WO/2024/022365A1
The present invention relates to a Wnt pathway inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inf...  
WO/2024/022433A1
Provided is a class of PRMT5 inhibitors represented by formula (X) or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof. Further provided are a preparation ...  
WO/2024/025393A1
The present invention relates to a novel salt of an imidazo[1,2-a]pyridine compound, a crystalline form thereof, and a preparation method, the novel salt being azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimid azo[1,2-a]pyridi...  
WO/2024/023666A1
This application relates to crystalline forms of an inhibitor of AKR1C3 dependent KARS. (Formula I)  
WO/2024/026081A1
The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.  
WO/2024/023266A1
The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...  
WO/2024/021957A1
The present invention relates to a PRMT5 inhibitor, a preparation method therefor, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a compound structure shown in formula (I), a pr...  
WO/2024/026410A2
The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and/or NTRK3), and pharmaceutical compositions thereof. In another aspect, the ...  
WO/2024/017863A1
The invention relates to novel compounds having the general formula (I) wherein R4, R5, X1, X2, X3 and Y1 are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/017856A1
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/020517A1
Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...  
WO/2024/020380A1
Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...  

Matches 151 - 200 out of 36,678